Intra-cellular Therapies Inc’s Sentiment

In Q4 2018 Intra-cellular Therapies Inc (NASDAQ:ITCI) big money sentiment decreased to 0.93, revealed SEC filings. So its down -0.01, from 2018Q3’s 0.94. 52 hedge funds increased or opened new stock positions, while 56 reduced and sold their stakes in Intra-cellular Therapies Inc so the sentiment dived. Funds own 36.55 million shares, down from 36.60 million shares in 2018Q3. Funds holding Intra-cellular Therapies Inc in top 10 was flat from 0 to 0 for the same number . 16 Investors Sold All; 40 Reduced Holdings; 37 increased holdings while 15 hedge funds bought holdings.

Biggest Intra-cellular Therapies Inc Investors

Rhenman & Partners Asset Management Ab owns 659,982 shares in Intra-cellular Therapies Inc as of Q4 2018. As of Q4 2018, 2.20 million shares of Intra-cellular Therapies Inc are owned by Bb Biotech Ag. First Midwest Bank Trust Division reported 327,226 shares. The New York-based fund General American Investors Co Inc have invested about 0.36% of the institutional investor’s stock portfolio in Intra-cellular Therapies Inc. The New York-based fund Samlyn Capital Llc looks positive on Intra-cellular Therapies Inc, owning 1.27 million shares.

Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including ParkinsonÂ’s and AlzheimerÂ’s disease.The firm is valued at $657.10 million. The firm is developing its lead drug candidate, lumateperone, known as ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, depression, and other neuropsychiatric and neurological disorders.Currently it has negative earnings. Lumateperone, a molecule, is in Phase III clinical development for the treatment of schizophrenia, bipolar depression, and agitation associated with dementia, including Alzheimer's disease.

ITCI touched $11.97 during the last trading session after $0.2 change.Intra-Cellular Therapies, Inc. has volume of 163,666 shares. Since April 18, 2018 ITCI has declined 24.89% and is downtrending. ITCI underperformed by 29.26% the S&P 500.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)’s earnings release is awaited by WallStreet on May, 2, Zacks reports. Last year’s earnings per share was $-0.65, while now analysts expect change of 36.92 % down from current $-0.89 earnings per share. Analysts at Wall Street see Intra-Cellular Therapies, Inc.’s 18.67 % negative EPS growth compared to $-0.75 earnings per share for last quarter.

Citadel Advisors Ltd Limited Liability Company invested in 1.05 million shs. Millennium Mgmt Limited Liability Corporation accumulated 0.02% or 925,505 shs. Metropolitan Life Ins New York accumulated 0% or 14,016 shs. Bank & Trust Of Montreal Can holds 5,578 shs. Baldwin Brothers Incorporated Ma has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Employees Retirement Association Of Colorado owns 5,687 shs. Barclays Public Limited Company stated it has 21,951 shs. Secor Capital Advsr Lp holds 0.04% or 26,444 shs. C Group Inc Hldg A S holds 146,671 shs or 0.02% of its capital. Prelude Management Lc invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Voya Inv Ltd Company invested in 19,478 shs or 0% of the stock. Profund Advsr Limited Liability Corporation reported 12,084 shs or 0.01% of all its holdings. Pennsylvania-based Sei Invests has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI). Macquarie Gp has 74,816 shs. Ubs Asset Mngmt Americas has invested 0% in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI).

Intra-Cellular Therapies, Inc. had 7 insider sales and 0 insider buys since November 9, 2018. This’s net activity of $1.99 million. 32,000 shs were sold by MARCUS JOEL S, worth $581,580 on Friday, November 9. Hineline Lawrence J. also sold $284,383 worth of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) on Friday, January 4. Vanover Kimberly E. sold 10,156 shs worth $116,979. Halstead Michael sold $284,418 worth of stock. 52,202 shs valued at $604,310 were sold by Mates Sharon on Friday, January 4.

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Ratings Coverage

Total analysts of 3 have positions in Intra-Cellular Therapies (NASDAQ:ITCI) as follows: 3 rated it a “Buy”, 0 with “Sell” and 0 with “Hold”. The positive are 100%. Since November 13, 2018 according to StockzIntelligence Inc Intra-Cellular Therapies has 4 analyst reports. On Wednesday, February 27 the rating was maintained by Cowen & Co with “Buy”. On Wednesday, February 27 Cantor Fitzgerald maintained the shares of ITCI in report with “Buy” rating.

For more Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) news released briefly go to: Globenewswire.com, Globenewswire.com, Seekingalpha.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2019 Congress of the Schizophrenia International Research Society – GlobeNewswire” released on April 15, 2019, “Intra-Cellular Therapies Presents Results from ITI-214 Phase 1/2 Clinical Trial in Patients with Parkinson’s Disease at 2018 American Neurological Association Annual Meeting – GlobeNewswire” on October 17, 2018, “Intra-Cellular Therapies completes NDA submission for Lumateperone – Seeking Alpha” with a publish date: September 28, 2018, “Intra-Cellular Therapies (ITCI) Presents At 37th Annual J.P. Morgan Healthcare Conference – Slideshow – Seeking Alpha” and the last “Intra-Cellular Therapies Announces Update on ITI-007-201 Clinical Trial for Treatment of Agitation in Patients with Probable Alzheimer’s Disease – GlobeNewswire” with publication date: December 18, 2018.